Ushbu ish iqtibos qilgan ishlar

55 ta ish

Ish: Exploring Cellular Immunotherapy Platforms in Multiple Myeloma

1. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma

   Kimberly Noonan, Carol Ann Huff, Janice M. Davis +16

   Maqola20152 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.296816

2. The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies

   Valentina Hoyos, Ivan Borrello

   Sharh maqola20162 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.296820

3. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site

   Claudia Zelle‐Rieser, Shanmugapriya Thangavadivel, R. Biedermann +5

   Maqola20162 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.296821

4. Global Manufacturing of CAR T Cell Therapy

   Bruce L. Levine, James Miskin, Keith Wonnacott +1

   Sharh maqola20172 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.296823

5. A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma

   Sung‐Hoon Jung, Hyunju Lee, Youn-Kyung Lee +5

   Maqola20172 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.296824

6. Immunotherapy for the treatment of multiple myeloma

   Sung‐Hoon Jung, Hyunju Lee, Manh-Cuong Vo +2

   Sharh maqola20172 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.296825

7. Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors

   Vincent Yi Sheng Oei, Marta Siernicka, Agnieszka Graczyk‐Jarzynka +14

   Maqola20182 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.296832

8. Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma

   Manh-Cuong Vo, Sung‐Hoon Jung, Tan-Huy Chu +6

   Maqola20182 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.296835

9. Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model

   Manh-Cuong Vo, Seoyun Yang, Sung‐Hoon Jung +6

   Maqola20182 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.296837

10. Cellular immunotherapy in multiple myeloma

    Manh-Cuong Vo, Thangaraj Jaya Lakshmi, Sung‐Hoon Jung +7

    Sharh maqola20192 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.296845

11. CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions

    Bradley D. Hunter, Caron A. Jacobson

    Maqola20192 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.296846

12. Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy

    Jianming Wu, Hemant Kumar Mishra, Bruce Walcheck

    Sharh maqola20192 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.296848

13. Gene editing for immune cell therapies

    Stefanie R. Bailey, Marcela V. Maus

    Sharh maqola20192 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.296851

14. Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy

    Cassie Chou, Cameron J. Turtle

    Sharh maqola20192 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.296855

15. How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma

    Adam D. Cohen, Noopur Raje, Jessica Fowler +3

    Sharh maqola20192 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.296857

16. Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma

    Tan-Huy Chu, Manh-Cuong Vo, Hye-Seong Park +4

    Maqola20202 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.296867

17. Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells

    Rebekka Duhen, Carmen Ballesteros‐Merino, Alexandra K. Frye +12

    Maqola20212 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.296875

18. Synthetic TILs: Engineered Tumor-Infiltrating Lymphocytes With Improved Therapeutic Potential

    Anaïs Jiménez-Reinoso, Daniel Nehme-Álvarez, Carmen Domínguez-Alonso +1

    Sharh maqola20212 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.296877

19. CAR T-cell therapy in multiple myeloma: more room for improvement

    Phaik Ju Teoh, Wee Joo Chng

    Sharh maqola20212 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.296883

20. Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21

    Jaya Lakshmi Thangaraj, Minh‐Trang Thi Phan, SoonHo Kweon +14

    Maqola20212 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.296889

21. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma

    Alejandra Leivas, Antonio Valeri, Laura Córdoba +15

    Maqola20212 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.296891

22. CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model

    Yu Yang Ng, Zhicheng Du, Xi Zhang +2

    Maqola20212 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.296892

23. Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma

    Hareth Nahi, Michael Chrobok, Stephan Meinke +20

    Maqola20222 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.296897

24. Novel IL-15 dendritic cells have a potent immunomodulatory effect in immunotherapy of multiple myeloma

    Tan-Huy Chu, Manh-Cuong Vo, Jaya Lakshmi Thangaraj +8

    Maqola20222 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.296905

25. Natural killer cells have a synergistic anti-tumor effect in combination with chemoradiotherapy against head and neck cancer

    Eun Kyung Jung, Tan-Huy Chu, Manh-Cuong Vo +10

    Maqola20222 iqtibos

    ABIABI:AkademIndex/openalex/2026.other.296911